Ocera Therapeutics has entered into a technology transfer and license deal with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH) discovery platform.
As part of the deal, Ocera will transfer ownership of equipment and materials related to the use of the MATCH technology, and grant a license to Genentech and Roche under its related intellectual property rights.
The deal will see Roche Group make a one-time payment to Ocera of $4m.
Ocera CEO Linda Grais said both the Genentech and Roche research organizations have an interest in the application of our MATCH technology.
"We are excited that we have found a good home for this technology where it may benefit the Roche Group and ultimately patients, while we focus our efforts on clinical development of OCR-002, our product candidate for the treatment of hepatic encephalopathy, a serious liver disorder," Grais said.